Literature DB >> 15073683

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.

Tara L Kieffer1, Mariel M Finucane, Richard E Nettles, Thomas C Quinn, Karl W Broman, Stuart C Ray, Deborah Persaud, Robert F Siliciano.   

Abstract

Human immunodeficiency virus (HIV) production continues in patients receiving highly active antiretroviral therapy (HAART) with undetectable (<50 copies/mL) virus loads. Our initial cross-sectional study showed that this viremia is composed of viruses that lack new resistance mutations to the HAART regimen. Here we describe a longitudinal, clonal genotypic analysis of plasma virus loads in treated adults who had undetectable virus loads. We document a continuous production of virus in 8 HIV-1-infected adults who maintained suppression of viremia for up to 15 months. Using analytical approaches for distinguishing selected resistance mutations from nonselected mutations and polymerase chain reaction errors, we detected no evolution of resistance in the reverse-transcriptase and protease genes. Sporadic resistance mutations were detected in some viral clones that were not selected for subsequently. Thus, in some patients, HAART suppresses replication to a level that does not allow the evolution of drug resistance over a time frame of years.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073683     DOI: 10.1086/382488

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  111 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

Review 2.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

Review 3.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Authors:  Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-27       Impact factor: 2.205

5.  Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia.

Authors:  Gudrun Naeth; Robert Ehret; Frank Wiesmann; Patrick Braun; Heribert Knechten; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2012-06-15       Impact factor: 3.402

Review 6.  Measuring the latent reservoir in vivo.

Authors:  Marta Massanella; Douglas D Richman
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

Review 7.  Recent trends in HIV-1 drug resistance.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  Curr Opin Virol       Date:  2013-09-07       Impact factor: 7.090

8.  G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.

Authors:  Tara L Kieffer; Patty Kwon; Richard E Nettles; Yefei Han; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

9.  Macrophages archive HIV-1 virions for dissemination in trans.

Authors:  Natalia Sharova; Catherine Swingler; Mark Sharkey; Mario Stevenson
Journal:  EMBO J       Date:  2005-05-26       Impact factor: 11.598

10.  Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Authors:  Carlum Shiu; Coleen K Cunningham; Thomas Greenough; Petronella Muresan; Victor Sanchez-Merino; Vincent Carey; J Brooks Jackson; Carrie Ziemniak; Lawrence Fox; Marvin Belzer; Stuart C Ray; Katherine Luzuriaga; Deborah Persaud
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.